Eagle-Derived Weissella confusa EG05 Prevents LPS-Induced Enteritis Through Modulation of Inflammation, Gut Barrier,...

Intestinal enteric inflammation can seriously harm animal health and lead to massive economic losses in livestock production. Probiotics have become a promising alternative to antibiotics for preventing and controlling enteritis. In this study, a novel lactic acid bacterium (LAB) was isolated from eagle feces and identified as Weissella confusa EG05 (W. confusa EG05), and its probiotic characteristics and protective effects on lipopolysaccharide (LPS)-induced enteritis in mice were evaluated. In vitro experiments showed that W. confusa EG05 has strong antimicrobial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus), good tolerance to acidic and bile salt conditions, high auto-aggregation ability and surface hydrophobicity, and no hemolytic activity. Whole-genome analysis further confirmed its safety and probiotic potential by revealing genes involved in adhesion, immune regulation, and stress tolerance. In mouse experiments, pretreatment with W. confusa EG05 alleviated LPS-induced intestinal pathological damage, inhibited the secretion of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6), promoted the expression of anti-inflammatory cytokine IL-10, enhanced the activities of antioxidant enzymes, and up-regulated the expression of tight junction proteins (Occludin, ZO-1). In addition, W. confusa EG05 restored gut microbiota homeostasis disturbed by LPS, increasing the abundance of beneficial genera and decreasing harmful bacteria. Taken together, these results suggest that W. confusa EG05 can effectively prevent LPS-induced enteritis in mice by modulating the inflammatory response, enhancing antioxidant capacity, protecting the intestinal barrier and the reshaping gut microbiota. These results indicate that W. confusa EG05 exhibits prominent probiotic potential in mouse models, providing a strain resource for the future development of microecological preparations.